Genesis Bioventures changes name to Abviva

The company said that it has changed its corporate name to emphasize its mission to commercialize the mammastatin serum assay and to pursue development of the mammastatin protein as a possible first line therapy against breast cancer.

The name change was approved by the shareholders at the 2007 annual shareholders meeting held on September 14, 2007 as part of the company’s completion of its reorganization and restructuring plan.

Douglas Lane, president and CEO, said: “We determined that the company requires a name that represents its mission and commitment to the mammastatin technology for breast cancer diagnostics and therapeutics. Abviva is a name inspired from a Latin phrase meaning ‘From Life’. Mammastatin is normally present in healthy women and therefore comes from life. This technology is used to develop and offer innovative diagnostic and therapeutic products ‘For Life’, beginning with the mammastatin serum assay.”